OncoMatch/Clinical Trials/NCT04516447
A Study of ZN-c3 in Patients With Ovarian Cancer
Is NCT04516447 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for solid tumor.
Treatment: ZN-c3 · Carboplatin · Pegylated liposomal doxorubicin · Paclitaxel · Gemcitabine · Bevacizumab — This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Tumor Agnostic
Ovarian Cancer
Disease stage
Grade: high-grade
Measurable disease per RECIST version 1.1.
Demographics
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L (excluding measurements after growth factors); Platelet count ≥ 100 × 10^9/L (excluding measurements after transfusion or growth factors)
Kidney function
Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min
Liver function
ALT and AST ≤3 × ULN (≤ 5 x ULN if due to liver metastases); total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in Gilbert's disease
Adequate hematologic and organ function as defined by the following criteria: ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; ALT and AST ≤3 × ULN (≤ 5 x ULN if due to liver metastases); total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in Gilbert's disease; Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 0264 · Aurora, Colorado
- Site 0104 · Boston, Massachusetts
- Site 0111 · St Louis, Missouri
- Site 0173 · New York, New York
- Site 0259 · Durham, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04516447 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages